Savitz Ryan
EVP, CFO & CBO
Savitz Ryan has filed 5 SEC Form 4 filings (20 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jul 13, 2026.
On the most recent filing, Savitz Ryan is listed as EVP, CFO & CBO at Dianthus Therapeutics, Inc. Inside the rolling window, Savitz Ryan reported no open-market purchases and 4 open-market sales totaling $14.3M in DNTH. The largest disclosed transaction in the window is a sale of 114,367 DNTH shares on Mar 31, 2026, worth $9.5M.
Companies traded
Other insiders at DNTH
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$14.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 9, 2025 | DNTH | Sale | $700K |
Frequently asked questions
How many SEC Form 4 filings has Savitz Ryan made?
Savitz Ryan has filed 5 SEC Form 4 filings (20 transaction rows) across 1 company since 2025.
Which companies does Savitz Ryan trade?
Savitz Ryan has filed SEC Form 4 disclosures for 1 company, including DNTH.
When was Savitz Ryan's most recent SEC Form 4 filing?
Savitz Ryan's most recent SEC Form 4 filing on Tracefour is dated Jul 13, 2026.
What is Savitz Ryan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Savitz Ryan is listed as EVP, CFO & CBO.
What is Savitz Ryan's total buy and sell value in the current window?
Inside the rolling retention window, Savitz Ryan bought $0 and sold $14.3M based on SEC Form 4 filings.
What was Savitz Ryan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 114,367 DNTH shares on 2026-03-31, worth $9.5M, per SEC Form 4 filings.